[
1. SUNG H, FERLAY J, SIEGEL RL, LAVERSANNE M, SOERJOMATARAM I, JEMAL A., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca Cancer J Clin, 2021;71:209–249.10.3322/caac.2166033538338
]Search in Google Scholar
[
2. GROOT PMD, WU CC, CARTER BW, MUNDEN RF. The epidemiology of lung cancer. Translational lung cancer research, 2018;7(3): 220–233.10.21037/tlcr.2018.05.06603796330050761
]Search in Google Scholar
[
3. NATIONAL COMPREHENSIVE CANCER NETWORK. Non-Small Cell Lung Cancer, Version 4.2021-March 3, 2021.
]Search in Google Scholar
[
4. AYOOLA A, BAROCHIA A, BELANI K, BELANI CP. Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update. Cancer Investigation, 2012;30:433–446.10.3109/07357907.2012.66669122571344
]Search in Google Scholar
[
5. SCHWARTZ LH, LITIERE S, VRIES ED, FORD R, GWYTHER S, MANDREKAR S., et al. RECIST 1.1 – Update and Clarification: From the RECIST Committee. Eur J Cancer, 2016; 62: 132–137.10.1016/j.ejca.2016.03.081573782827189322
]Search in Google Scholar
[
6. YOSHIDA T, YOH K, NIHO S, UMEMURA S, MATSUMOTO S, OHMATSU H., et al. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboringan EGFR mutation. Lung Cancer, 2015.10.1016/j.lungcan.2015.09.02526604031
]Search in Google Scholar
[
7. BARRON F, CARDONA AF, CORRALES L, RAMIREZ-TIRADO LA, CABALLE-PEREZ E, SANCHEZ G., et al. Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation. J Thorac Dis, 2018;10(4):2166–2178.10.21037/jtd.2018.03.106594949029850120
]Search in Google Scholar
[
8. GOMEZ XE, SOTO A, GOMEZ MA. Survival and prognostic factors in non-small cell lung cancer patients with mutation of the EGFR gene treated with tyrosine kinase inhibitors in a peruvian hospital. Am J Cancer Res, 2019;9(5):1009–1016.
]Search in Google Scholar
[
9. KIM SY, MYUNG JK, KIM HR, NA II, KOH JS, BAEK HJ., et al. Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma. Tuberc Respir Dis, 2019;82:62–70.10.4046/trd.2018.0004630433129926551
]Search in Google Scholar
[
10. IGAWA S, SASAKI J, OTANI S, ISHIHARA M, TAKAKURA A, KATAGIRI M., et al. Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations. Oncology, 2015;89:275–280.10.1159/00043870326335629
]Search in Google Scholar
[
11. DOUILLARD JY, OSTOROS G, COBO M, CIULEANU T, MCCORMACK R, WEBSTER A., et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. British Journal of Cancer, 2014;110:55–62.10.1038/bjc.2013.721388730924263064
]Search in Google Scholar
[
12. ROTELLA V, FORNARO L, VASILE E, TIBALDI C, BOLDRINI L, CHELLA A., et al. EGFR and KRas mutations in women with lung adenocarcinoma: implications for treatment strategy definition. Journal of Experimental and Clinical Cancer Research, 2014;33:7710.1186/s13046-014-0077-6419872625300933
]Search in Google Scholar
[
13. YU JY, YU SF, WANG SH, BAI H, ZHAO J, AN TT., et al. Clinical outcomes of EGFRTKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 2. Chinese Journal of Cancer, 2016;35:30.10.1186/s40880-016-0086-2480287527001083
]Search in Google Scholar
[
14. OUYANG W, YU J, HUANG Z, CHEN G, LIU Y, LIAO Z., et al. Risk factors of acquired T790M mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. Journal of Cancer, 2020; 11(8):2060–2067.10.7150/jca.37991705292432127933
]Search in Google Scholar
[
15. WHEATLEY-PRICE P, DING K, SEYMOUR L, CLARK GM, SHEPHERD FA. Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 2008;26(14):2350–2357.10.1200/JCO.2007.15.228018467727
]Search in Google Scholar
[
16. ROZENSZTAJN N, RUPPERT AM, LAVOLE A, LEPRIEUR EG, DURUISSEAUX M, VIEIRA T., et al. Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors. Cancer Medicine, 2014;3(1):61-69.10.1002/cam4.180393039024408092
]Search in Google Scholar
[
17. TSAI MJ, HUNG JY, LEE MH, KUO CY, TSAI YC, TSAI YM., et al. Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors. Cancer, 2018; 10.10.3390/cancers10110434626644630428509
]Search in Google Scholar
[
18. ZHANG P, NIE X, BIE Z, LI L. Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma. Medicine, 2018;97:910.1097/MD.0000000000010006585173829489642
]Search in Google Scholar
[
19. HASEGAWA Y, ANDO M, MAEMONDO M, YAMAMOTO S, ISA SI, SAKA H., et al. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR)Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials. The Oncologist, 2015;20:307–315.10.1634/theoncologist.2014-0285435079725657199
]Search in Google Scholar
[
20. TANIGUCHI Y, TAMIYA A, NAKAHAMA K, NAOKI Y, KANAZU M, OMACHI N., et al. Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors. Oncology Letters, 2017;14:7589–7596.10.3892/ol.2017.7125575525829344206
]Search in Google Scholar
[
21. HSU F, CALUWE AD, ANDERSON D, NICHOL A, TORIUMI T, HO C. Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations. Curr Oncol, 2017 Aug;24(4):228–233.10.3747/co.24.3496557645828874890
]Search in Google Scholar
[
22. XU C, YAO X, LI T, WANG J, AN B, WANG J., et al. Pretreatment neutrophil-tolymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer. Transl Cancer Res, 2020;9(4):2875–2883.10.21037/tcr.2020.02.28879761135117644
]Search in Google Scholar
[
23. TANG M, GAO X, SUN H, TIAN S, DONG J, LIU Z., et al. Neutrophil-Lymphocyte Ratio as a Prognostic Parameter in NSCLC Patients Receiving EGFR-TKIs: A Systematic Review and Meta-Analysis. Journal of Oncology, 2021.10.1155/2021/6688346784025733542732
]Search in Google Scholar
[
24. PHAN TT, HO TT, NGUYEN HT, NGUYEN HT, TRAN TB, NGUYEN ST. The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI. International Journal of General Medicine, 2018;11:423–430.10.2147/IJGM.S174605625010630510441
]Search in Google Scholar
[
25. URIBE-QUEROL E, ROSALES C. Neutrophils in Cancer: Two Sides of the Same Coin. Journal of Immunology Research, 2015;2015.10.1155/2015/983698470693726819959
]Search in Google Scholar
[
26. WON YW, HAN JY, LEE GK, PARK SY, LIM KY, YOON KA., et al. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. J Clin Pathol, 2011;64:947e952.10.1136/jclinpath-2011-20016921725039
]Search in Google Scholar
[
27. JIANG H, ZHU M, LI Y, LI Q. Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer. Mol Clin Oncol, 2019; 11(3): 301–30810.3892/mco.2019.1881663621031384460
]Search in Google Scholar
[
28. MATSUO N, AZUMA K, SAKAI K, HATTORI S, KAWAHARA A, ISHII H., et al. Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. Scientific Report, 2016;6.10.1038/srep36458509555127811988
]Search in Google Scholar
